Competing interests
S.L. declares being a GBG Forschungs GmbH employee (CEO). The institution received research grants from Abbvie, AstraZeneca, Celgene, Novartis, Pfizer, Daiichi Sankyo, Gilead, Molecular Health, Menarini Group and Greenwich LifeSciences; consulting fees from Pfizer, Roche, Novartis, Seattle Genetics, Lilly, AstraZeneca/MedImmune, Bristol Myers Squibb, Abbvie, Amgen, Diiachi Sankyo, GlaxoSmithKline, Eisai Europe, Relay Therapeutics, Sanofi, Olema Pharmaceuticals, Menarini Group, MSD Oncology, BeiGene, Bicycle Therapeutics, BMS and Jazz Pharmaceuticals; speaking fee and honoraria from AstraZeneca, Daiichi Sankyo Europe GmbH, Novartis, Pfizer, Roche, Gilead Sciences, Seattle Genetics, Menarini Group, Agendia, Bayer, Medscape, MSD, Stemline Therapeutics and Streamedup!; and travel support from AstraZeneca, Roche and MSD. GBG Forschungs GmbH has licensing fees from VMscope GmbH. In addition, GBG Forschungs GmbH has the following patents pending: EP14153692.0, EP21152186.9 and EP19808852.8. G.T. reports research support from Exact Sciences, Inc (grant/contract). V.N. declares being a GBG Forschungs GmbH employee. GBG Forschungs GmbH received research grants from Abbvie, AstraZeneca, Celgene, Novartis, Pfizer, Daiichi Sankyo, Gilead, Molecular Health, Menarini Group and Greenwich LifeSciences (paid to the institution); consulting fees from Pfizer, Roche, Novartis, Seattle Genetics, Lilly, AstraZeneca/MedImmune, Bristol Myers Squibb, Abbvie, Amgen, Diiachi Sankyo, GlaxoSmithKline, Eisai Europe, Relay Therapeutics, Sanofi, Olema Pharmaceuticals, Menarini Group, MSD Oncology, BeiGene, Bicycle Therapeutics, BMS, Jazz Pharmaceuticals (paid to the institution); and speaking fee and honoraria from AstraZeneca, Daiichi Sankyo Europe GmbH, Novartis, Pfizer, Roche, Gilead Sciences, Seattle Genetics, Menarini Group, Agendia, Bayer, Medscape, MSD, Stemline Therapeutics and Streamedup! (paid to the institution). GBG Forschungs GmbH has licensing fees from VMscope GmbH. In addition, GBG Forschungs GmbH has the following patents pending: EP14153692.0, EP21152186.9 and EP19808852.8. P.R. reports employment with University of Pittsburgh, University of Pittsburgh Physicians and NSABP Foundation, and grant and research support for NSABP Foundation from Genentech/Roche, Artera, Daiichi Sankyo, AstraZeneca and Exact Sciences. S.R. declares being a GBG Forschungs GmbH employee. GBG Forschungs GmbH received research grants from Abbvie, AstraZeneca, Celgene, Novartis, Pfizer, Daiichi Sankyo, Gilead, Molecular Health, Menarini Group, Greenwich LifeSciences (paid to the institution); consulting fees from Pfizer, Roche, Novartis, Seattle Genetics, Lilly, AstraZeneca/MedImmune, Bristol Myers Squibb, Abbvie, Amgen, Diiachi Sankyo, GlaxoSmithKline, Eisai Europe, Relay Therapeutics, Sanofi, Olema Pharmaceuticals, Menarini Group, MSD Oncology, BeiGene, Bicycle Therapeutics, BMS and Jazz Pharmaceuticals (paid to the institution); and speaking fees and honoraria from AstraZeneca, Daiichi Sankyo Europe GmbH, Novartis, Pfizer, Roche, Gilead Sciences, Seattle Genetics, Menarini Group, Agendia, Bayer, Medscape, MSD, Stemline Therapeutics and Streamedup! (paid to the institution). GBG Forschungs GmbH has licensing fees from VMscope GmbH. In addition, GBG Forschungs GmbH has the following patents pending: EP14153692.0, EP21152186.9 and EP19808852.8. M.R. (or her institution) reports honoraria and/or consultancy fee from AstraZeneca, Daiichi Sankyo, Gilead, Lilly, MSD, Novartis, Pfizer, Roche, OnkowissenTV, Seagen, Streamed Up and Somatex. M.R. also reports travel support from AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Novartis, Pfizer and Roche. A.S. reports research grants from Celgene, Roche and AbbVie; personal fees (travel expenses) from Celgene, Roche, Pfizer and AstraZeneca; and personal fees (honoraria) from Roche, Celgene, Pfizer, AstraZeneca, Novartis, MSD, Tesaro, Lilly, Seagen, Gilead, GSK, Bayer, Amgen and Pierre Fabre. C.H. declares being on the AstraZeneca/Daiichi Sankyo speakers bureau (2021 only) and an advisory board member for AstraZeneca, Gilead, Biotheranostics and Tolmar, and receives honoraria from MJH/Curio Science. S.S. reports travel fees from Abbvie and Novartis, and consulting fees from Novartis, as well as having an advisory relationship with Roche, all outside the submitted work. She was also a GBG Forschungs GmbH employee until 2024. R.B. reports receiving consultation fees from GE Healthcare and being on the speaker’s bureau for AstraZeneca, but both of these relationships have ended. T.K. reports grants from H.W. & J. Hector-Stiftung and BMBF, during the conduct of the study. T.K. has a patent application EP24210258 pending and patent WO2020109570A1 pending. F.M. reports fees for consulting or advisory roles from Novartis, Pfizer, AstraZeneca, MSD, Daiichi Sankyo and Pierre Fabre; speakers’ bureau fees from Pfizer and Novartis; research funding from Pfizer (paid to the institution); and travel, accommodation and other expenses from Pfizer, Novartis, Gilead Sciences and Lilly. J.H. received honoraria from Lilly, Novartis, Roche, Pfizer, AstraZeneca, Gilead, Daiichi, Stemline, MSD and Abbvie; had a consulting, advisory relationship with Lilly, Novartis, Roche, Pfizer, AstraZeneca, Gilead, Daiichi and Abbvie; and received travel expenses: Roche, Daiichi, Gilead and AstraZeneca. J.-F.B. has no personal conflicts of interest to disclose; he receives funding from Roche for the conduct of the B-59 trial through NSABP Foundation. A.R.-L. reports fees for consulting or advisory roles from Roche, Pfizer, Novartis, Lilly, AstraZeneca, Daiichi Sankyo, Gilead, MSD, Seagen and Menarini; research funding from Roche, Novartis, Pfizer, Lilly, Astellas, Bristol Myers, AstraZeneca, MSD, Radius, Zymeworks, GILEAD, GEICAM and Seagen (paid to the institution); and speakers’ bureau fees from Roche, Pfizer, Novartis, Lilly, AstraZeneca, GILEAD, Daiichi Sankyo, Eisai, MSD, Seagen, SEOM and GEICAM. J.M. declares being an employee and shareholder of F. Hoffmann-La Roche, Ltd. E.P.M. declares being an Advent Health employee; he receives consulting fees from Merck, Exact Sciences, Novartis, GE Healthcare, Biotheranostics, Delphi Diagnostics and Lilly and speaker fees from Merck, Novartis and Exact Sciences. C.D. reports grants from EU-H2020, BMBF, German Cancer Aid and GBG Forschungs GmbH, during the conduct of the study; personal fees from Roche, MSD oncology, Daiichi Sankyo, AstraZeneca, BioNTech and Merck; and institutional grants from Myriad, outside the submitted work. C.D. has a patent VMscope digital pathology software with royalties paid, a patent application EP24210258 pending, as well as patents WO2020109570A1 and WO2015114146A1 pending and WO2010076322A1, issued. N.W. reports employment at NSABP Foundation, Inc., UPMC Hillman Cancer Center and University of Pittsburgh School of Medicine; he is Chair of the Board of Directors at the NSABP Foundation, Inc. and receives grants to the institution from Breast Cancer Research Foundation. C.E.G. reports employment with University of Pittsburgh, University of Pittsburgh Physicians and NSABP Foundation; grant and research support for NSABP Foundation from Genentech/Roche, Artera, Daiichi Sankyo, AstraZeneca and Exact Sciences; travel support from AstraZeneca, Genentech/Roche, Exact Sciences and Merck; and honoraria from Merck and TerSera. All other authors declare no potential conflict of interest relevant to this article.
